Conference Reports for NATAP

62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back

VX-222/Telaprevir in Combination With Peginterferon-alfa-2a and Ribavirin in Treatment-naïve Genotype 1 HCV Patients Treated for 12 Weeks: ZENITH Study, SVR12 Interim Analysis       Reported by Jules Levin AASLD Nov 5-9 2011 SF   David R Nelson*1, Edward J Gane2, Ira M Jacobson3, Adrian M Di Bisceglie4, Katia Alves5, Margaret J Koziel5, Cynthia De Souza5, Tara L Kieffer5, Shelley George5, Maria Rosario5, Robert S Kauffman5, Mark S Sulkowski6 1University of Florida College of Medicine, Gainesville, FL, USA; 2Auckland City Hospital, Auckland, New Zealand; 3Weill Cornell Medical College, New York, NY, USA; 4Saint Louis University School of Medicine, Saint Louis, MO, USA; 5Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 6Johns Hopkins University, Baltimore, MD, USA.